In case you missed this:
ERLEADA
Now Available in the U.S.Addition of 240mg strength allows prescribers flexibility to prescribe one 240mg tablet or four 60mg tablets once-daily based on patient needsHORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States.
The introduction of the 240mg tablet provides the first- and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to prescribe the approved 240mg once-daily dose of ERLEADA® in either one 240mg tablet or four 60mg tablets.
The single-tablet option may be preferable for patients in need of reducing their total number of daily pills.